By: Sofia Arreguin

Photo Credit: The Defeating Epilepsy Foundation

SLC2A1 Gene Mutation and Epilepsy

What is SLC2A1?

The brain, often referred to as the “command center,” is an essential organ that controls cognitive processes and automatic bodily functions that keep the body alive. To maintain its health and ability to oversee physiological processes, the brain requires energy, specifically oxygen and glucose, to be transported through the bloodstream into its surrounding cerebrospinal fluid (CSF), allowing the nutrients to be received and used. One manner in which this process occurs is through the function of the glucose transporter protein type 1 (GLUT1), produced by the SLC2A1 gene.

Integrated within the outer membrane of cells, GLUT1 is identified as a protein that carries glucose, or simple sugars, from the blood into brain cells to be used as fuel (National Library of Medicine, 2014). Without this protein transporter, glucose cannot easily reach the brain, as the blood-brain barrier prevents glucose from passing through its lipid-based protective layer, which is composed of tightly packed endothelial cells; its wall prevents certain substances from passing through (Cleveland Clinic, 2023). Glucose is characterized by its hydrophilic (“water-attracting”) and water-soluble structure, whereas the blood-brain barrier possesses lipophilic (“fat-attracting”) characteristics. Normally, hydrophilic and lipophilic molecules repel each other; therefore, glucose, by itself, is repelled by the blood-brain barrier, preventing it from reaching the brain (Cleveland Clinic, 2023). However, with GLUT1, glucose can be transported between brain cells, helping support neuronal health.

SLC2A1-Related Epilepsy

Variants in the SLC2A1 gene result in a condition known as GLUT1 Deficiency Syndrome (GLUT1 DS), defined by a disturbance in brain energy metabolism, where GLUT1 is unable to efficiently transport glucose across the blood-brain barrier (Wang et al., 2025). As a result, the brain is deprived of sufficient amounts of glucose to meet its energy requirements, producing neurological issues, such as developmental delays, seizures, movement problems, and intellectual disability; however, not all affected individuals experience all symptoms to the same degree.

Infancy to Early Childhood

Symptoms usually begin to appear during infancy to early childhood years, specifically between the ages of zero and four. At birth, infants have a normal head size, but as they mature, the growth of their skull and brain does not maintain the same pace, resulting in an abnormally small head size, or a condition named microcephaly (National Library of Medicine, 2022). Sudden, involuntary, and repetitive eye-head movements become common, where the eyes shift to look towards different focus points in the environment, accompanied by head movements in the same direction (Wang et al., 2025). Children also experience drug-resistant seizures frequently during their first months of life, and less frequently after two years of age. Seizure types include generalized seizures, early-onset childhood absence epilepsy, where children stare blankly, endure eye or lip spasms, and cease any previous activity, and myoclonic-atonic seizures (Doose Syndrome), which involve jerky limb movements followed by a drop in muscle tone, causing the child to collapse (Wang et al., 2025). As they mature, they encounter other difficulties, such as intellectual disabilities, developmental delays, and movement disorders.

Later Childhood to Adulthood

 Symptoms continue to persist later in childhood and adulthood, such as seizures, yet they become less common and frequent during these years. Patients may experience paroxysmal movement disorders, which include involuntary muscle movements, a loss of muscle coordination (ataxia), fidgety, twisting limb movements (choreoathetosis), repetitive muscle contractions (dystonia), paralysis, and periods of muscle weakness or stiffness that alternate between both sides of the body (alternating hemiplegia) (Wang et al., 2025). Spasticity, a persistent movement disorder, may also arise, consisting of the simultaneous contraction of multiple muscles when the individual attempts to move or even when at rest. Additional disorders experienced include speech difficulties (dysarthria), which involve paralysis of muscles employed for speech, intellectual disability, a diagnosis of autism spectrum disorder, and neurobehavioral manifestations, which involve some characteristics of attention-deficit/hyperactivity disorder (ADHD) and autism.

Other symptoms include paroxysmal non-motor episodes, including migraines, cyclic vomiting syndrome (CVS), defined by repeated attacks of nausea and vomiting in between periods of normal health, and sleep spells, primarily hypersomnolence, where the patient experiences excessive sleepiness during the day and oftentimes has sudden episodes of sleep known as “sleep attacks” (Wang et al., 2025). Some patients experience confusion, an absence of energy (lethargy), and headaches, as well. Most symptoms can be triggered by fasting, encountering stressors, and anxiety; however, such symptoms can be improved or managed through medically suggested treatments.

Diagnosis

 The diagnosis for GLUT1 DS can be determined by three criteria: clinical features, hypoglycorrhachia, and pathogenic sequence variations. Clinical features involve the developmental delays, movement disorders, and seizures; hypoglycorrhachia is characterized by reduced glucose levels in the CSF, specifically glucose levels below 52 mg/dL; and pathogenic sequence variations refer to the mutations present within the gene’s structure, ultimately resulting in the production of faulty proteins (Johnson et al., 2023). Hypoglycorrhachia can be determined through a lumbar puncture procedure, involving the insertion of a needle into the lower back to collect CSF, which is then examined in a laboratory to identify glucose concentration levels. The primary finding to conclude a diagnosis revolves around low glucose levels in the brain, while normal blood glucose levels remain (Wang et al., 2025). This suggests that although the body possesses a sufficient amount of glucose, the brain is being starved. The use of molecular genetic testing for identifying pathogenic variants is also employed, especially comprehensive genomic testing and gene-targeted testing.

Comprehensive genomic testing

This form of testing involves two types of sequencing: exome sequencing and genome sequencing. To begin genome sequencing, a sample of the patient’s saliva, blood, or tissue is collected. Their DNA is then extracted from the sample and placed within technological tools, such as Next-Generation Sequencing (NGS), allowing the DNA sequence to be read and analyzed (Centers for Disease Control and Prevention, 2024). Fragments of the sequence are then compared to a standard genome, permitting researchers to identify where the variant exists. For instance, the computer may find that compared to the standard genome, the patient’s genome contains a chemical base in an incorrect location. This then prompts researchers to further investigate whether this misplacement has a connection to an illness or medical condition. The same process is completed for the exome sequencing, but the main difference is that instead of analyzing the whole gene, the exome sequencing focuses only on the exons, which are certain sections of the DNA sequence that provide the instructions for creating proteins.

Gene-targeted testing

This form of testing involves a multigene panel. Similar to comprehensive genome testing, the multigene panel test involves the extraction of DNA from the patient’s saliva, blood, or tissue. However, researchers focus on genes known to have an association with a certain disease or medical condition. Once the DNA fragments are read and amplified, the NGS sequences millions of DNA fragments simultaneously, allowing researchers to compare the patient’s gene with a corresponding standard gene (Massive Bio, 2026).

Treatment

Although there is no cure, this rare but manageable condition has viable treatment options to improve symptoms. A prominent treatment choice is the ketogenic diet therapy (KDT). This diet supplies the brain with ketones, a supplemental energy source, that assists in the brain’s energy metabolism process (Wang et al., 2025). Since the variant in the SLC2A1 gene produces inefficient GLUT1 transporters, glucose cannot be carried through the blood-brain barrier. With KDT, the body turns to relying on lipids by burning fat, effectively producing ketone bodies to be used as fuel, rather than continuing to rely on carbohydrates and proteins to use glucose as fuel. This diet seems beneficial since ketone bodies can be transported across the blood-brain barrier by the monocarboxylic transporter 1 (MCT1) and used by the brain’s cells; the diet offers an efficient alternative to providing the brain with fuel (Wang et al., 2025). Although this may help manage seizures, supplementing 50 mg/kg per day of L-carnitine is recommended, as the KDT includes insufficient amounts of  L-carnitine, a vital protein necessary for metabolizing fats and, therefore, aiding in energy production (Wang et al., 2025). Patients are also advised to avoid consuming carbohydrates and to refrain from receiving intravenous fluids to maintain a state of chronic ketosis; restricting carbohydrates forces the body to rely on fats, and intravenous fluids may dilute the effectiveness of the diet.

Antiseizure medications (ASMs) are also known to improve symptoms, but patients are cautioned to avoid valproic acid treatment as it puts individuals at a heightened risk of obtaining Reye-like disease, a condition that involves vomiting, seizures, states of confusion, advancement into coma, and further inhibits the transport of glucose (Wang et al., 2025). For neurobehavioral manifestations, applied behavior therapy (ABA) is recommended since it aims to improve children’s social and behavioral traits through a one-on-one session between the child and a certified behavior analyst (Wang et al., 2025). For older individuals, a modified diet therapy, the modified Atkins diet (MAD), is advised. With this diet, older individuals are not strictly prevented from consuming the carbohydrates and protein that are normally prohibited by the ketogenic diet. It also provides for simpler measurements, such as using common kitchen measuring tools, rather than needing to use a scale to weigh food. Such a diet provides more simplicity, allows older individuals to maintain muscle mass by having fewer restrictions on food consumption, and aids in slowing or preventing cognitive decline.

Seeking medical help to manage symptoms may help affected individuals lead an improved way of life. Although there is no cure, researchers are attempting to find other therapies and treatment options, offering alternatives to those who do not respond well to current medications or therapy. Offering support to affected individuals, or receiving support if affected, may also be beneficial in helping maintain a caring and loving environment.

References

Centers for Disease Control and Prevention. (2024). What is Genomic Sequencing? U.S. Department of Health and Human Services. https://www.cdc.gov/advanced-molecular-detection/about/what-is-genomic-sequencing.html

Cleveland Clinic. (2023, April 17). Blood-Brain Barrier. https://my.clevelandclinic.org/health/body/24931-blood-brain-barrier-bbb

Johnson, D., et al. (2023). Toward Precision Medicine for Genetic Epilepsies: Glucose Transporter Type 1 Deficiency Syndrome. Practical Neurology. https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/toward-precision-medicine-for-genetic-epilepsies-glucose-transporter-type-1-deficiency-syndrome/32055/

Massive Bio. (2026, March 4). Multigene Panel Test. https://massivebio.com/multigene-panel-test-bio/

National Library of Medicine. (2022, October 28). GLUT1 deficiency syndrome. MedlinePlus. https://medlineplus.gov/genetics/condition/glut1-deficiency-syndrome/

National Library of Medicine. (2014, March 1). SLC2A1 gene. MedlinePlus. https://medlineplus.gov/genetics/gene/slc2a1/

Wang, D., et al. (2025). Glucose Transporter Type 1 Deficiency Syndrome. In M.P. Adam, S. Bick, & G.M. Mirzaa (Eds.), GeneReviews. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK1430/